Evidence map›Paper›PMID 29084206›Full record

ArticleBone marrow transplantation2018

Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients.

P Ke, X-B Bao, X-H Hu, J Zhuang, X-J Wu, Y-J Liu, X-F He, D-P Wu, S-L Xue, X Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

P KeJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
X-B BaoJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
X-H HuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
J ZhuangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
X-J WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Y-J LiuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
X-F HeJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
D-P WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
S-L XueJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
X MaJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to evaluate the strategy of haploidentical (HID) stem cell combined with a small doses of umbilical cord blood (UCB) from a third-party donor transplantation (haplo-cord transplant) for treatment of myelodysplastic syndromes (MDS), by comparing with identical-sibling donor (ISD) transplantation. Eighty-five patients were included between January 2012 and December 2015, with a median 40 years old. Forty-eight patients received haplo-cord transplant and 37 patients received ISD transplant. Haplograft engraftment succeeded in all haplo-cord patients. For haplo-cord and ISD transplantation, adjusted cumulative incidences of grades 2-4 acute GvHD at 100 days were 27 and 11% (P=0.059); adjusted cumulative incidences of chronic GvHD at 2 years were 22 and 34% (P=0.215). The 2-year adjusted probabilities of overall survival were 64 and 70% (P=0.518), and of relapse-free survival were 56 and 66% (P=0.306). The 2-year adjusted cumulative incidences of relapse were 12 and 14% (P=0.743), and of non-relapse mortality were 33 and 23% (P=0.291). In conclusion, haplo-cord-HSCT achieves outcomes similar to those of ISD-HSCT for MDS and the haplo-cord-HSCT may potentially improve the outcome of HID- and UCB-HSCT alone. Thus, the haplo-cord transplantation may be a better valid alternative for MDS when an ISD is not available.

Indexed as

AdolescentAdultChildCord Blood Stem Cell TransplantationDisease-Free SurvivalFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesTransplantation ConditioningYoung Adult

Identifiers

PMID29084206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.